Ziyad Al-Aly
Ziyad Al-Aly is a clinical epidemiologist at Washington University in St. Louis. He specializes in studying the health effects of medications and chronic diseases. Recently, he commented on a small study that suggested potential vision problems associated with GLP-1 receptor agonists, emphasizing the need for larger, controlled studies to better understand the implications and risks of these widely used diabetes and weight-loss drugs.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Guatemala | 1 | 8.00 | 0.37% | +0% | 17,915,568 | 66,849 | $82,000 | 306$ |
| Taiwan | 1 | 8.00 | 0.48% | +0% | 23,816,775 | 114,504 | $670,000 | 3,221$ |
| Totals | 2 | 41,732,343 | 181,353 | $752,000 | 3,527$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Guatemala:
Ziyad Al-Aly explains that GLP-1 could act on the brain's reward circuit, reducing cravings associated with substance use.
8
Taiwan:
Ziyad Al-Aly is the study’s lead author and a chief researcher at the VA St. Louis Health Care System.
8
Argentina:
Ziyad Al-Aly is a clinical epidemiologist at Washington University in St. Louis who commented on the study's findings.
7
Honduras:
Ziyad Al-Aly is a senior clinical epidemiologist at the University of Washington in St. Louis, Missouri.
7
Liechtenstein:
Ziyad Al-Aly is the senior author of the study examining the effects of GLP-1 analogs.
8
India:
Dr. Ziyad Al-Aly is the chief of research and development at the VA St. Louis Health Care System and a clinical epidemiologist at Washington University in St. Louis.
8
United States:
Ziyad Al-Aly, a clinical epidemiologist at Washington University in St. Louis, was not involved in the study but shared his comments on the findings.
5